Intech Investment Management LLC Raises Stake in Gilead Sciences, Inc. $GILD

Intech Investment Management LLC raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 52.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 215,508 shares of the biopharmaceutical company’s stock after purchasing an additional 74,506 shares during the quarter. Intech Investment Management LLC’s holdings in Gilead Sciences were worth $23,893,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the company. Price T Rowe Associates Inc. MD grew its stake in Gilead Sciences by 314.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock valued at $1,647,484,000 after acquiring an additional 11,156,382 shares during the period. Nuveen LLC acquired a new position in shares of Gilead Sciences during the 1st quarter worth approximately $620,415,000. Kingstone Capital Partners Texas LLC purchased a new stake in Gilead Sciences in the 2nd quarter valued at $238,083,000. Los Angeles Capital Management LLC raised its stake in Gilead Sciences by 422.6% during the first quarter. Los Angeles Capital Management LLC now owns 2,523,036 shares of the biopharmaceutical company’s stock worth $282,706,000 after purchasing an additional 2,040,261 shares during the period. Finally, Vanguard Group Inc. lifted its holdings in Gilead Sciences by 1.7% in the first quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock valued at $13,162,606,000 after acquiring an additional 1,942,433 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Gilead Sciences

In related news, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction on Monday, September 15th. The shares were sold at an average price of $113.57, for a total value of $340,710.00. Following the completion of the sale, the insider owned 113,193 shares in the company, valued at $12,855,329.01. This represents a 2.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Deborah H. Telman sold 53,646 shares of the company’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $122.85, for a total transaction of $6,590,411.10. Following the completion of the sale, the executive vice president directly owned 43,676 shares of the company’s stock, valued at $5,365,596.60. The trade was a 55.12% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 94,646 shares of company stock valued at $11,311,286. Insiders own 0.27% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on GILD shares. Morgan Stanley increased their price objective on shares of Gilead Sciences from $143.00 to $147.00 and gave the stock an “overweight” rating in a research report on Friday, October 31st. Sanford C. Bernstein reiterated an “outperform” rating on shares of Gilead Sciences in a research note on Monday, November 3rd. Wells Fargo & Company boosted their target price on Gilead Sciences from $140.00 to $145.00 and gave the stock an “overweight” rating in a research note on Friday, October 31st. Weiss Ratings reiterated a “buy (b)” rating on shares of Gilead Sciences in a research note on Wednesday, October 8th. Finally, Rothschild & Co Redburn boosted their target price on shares of Gilead Sciences from $143.00 to $153.00 in a research note on Monday, November 10th. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $129.13.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $125.02 on Friday. The stock’s 50-day moving average is $117.44 and its two-hundred day moving average is $112.77. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. Gilead Sciences, Inc. has a 1 year low of $86.08 and a 1 year high of $127.68. The firm has a market cap of $155.11 billion, a price-to-earnings ratio of 24.90, a PEG ratio of 0.81 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. The firm had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business’s revenue was up 3.0% on a year-over-year basis. During the same period in the prior year, the firm earned $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be given a dividend of $0.79 per share. The ex-dividend date is Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is 48.99%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.